Clinical Trials
Response of Patients on Surveillance for Prostate Cancer to DutasterideCondition: Prostate CancerIntervention: Drug: Dutasteride Sponsors: Sunnybrook Health Sciences Centre; Toronto Sunnybrook Regional Cancer Centre Completed Fri, 03 Feb 2012 12:00:00 EST Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed ImplantationCondition: Prostate CancerInterventions: Drug: avodart; Drug: Placebo Sponsors: Bay State Clinical Trials, Inc.; GlaxoSmithKline Completed Wed, 10 Dec 2008 12:00:00 EST ARTS - AVODART After Radical Therapy For Prostate Cancer StudyConditions: Neoplasms, Prostate; Prostate Cancer After a Radical TreatmentInterventions: Drug: Avodart; Other: placebo Sponsor: GlaxoSmithKline Completed Wed, 14 Nov 2007 12:00:00 EST MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate CancerConditions: Nonmalignant Neoplasm; Prostate CancerIntervention: Drug: dutasteride Sponsor: University of California, San Francisco Completed Mon, 30 Jun 2008 12:00:00 EDT Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of EfficacyCondition: Alcohol Use DisorderInterventions: Drug: Dutasteride Capsules; Drug: Placebo Capsules Sponsors: UConn Health; National Institute on Alcohol Abuse and Alcoholism (NIAAA) Recruiting Mon, 23 Sep 2019 12:00:00 EDT AVODART® Alopecia Post-marketing Surveillance (PMS)Condition: AlopeciaIntervention: Drug: Dutasteride Sponsor: GlaxoSmithKline Completed Fri, 30 Oct 2009 12:00:00 EDT Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic ObstructionCondition: Benign Prostatic HyperplasiaIntervention: Drug: Dutasteride Sponsors: Samsung Medical Center; GlaxoSmithKline Completed Fri, 23 Jan 2009 12:00:00 EST Pharmacokinetic Study of Single Dose Dutasteride in Healthy SubjectsConditions: Alcohol Related Disorders; Alcoholism; Alcohol AbuseIntervention: Drug: Dutasteride Sponsors: UConn Health; National Institutes of Health (NIH); National Institute on Alcohol Abuse and Alcoholism (NIAAA) Completed Thu, 04 Dec 2008 12:00:00 EST Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate CancerCondition: Prostate CancerInterventions: Drug: Dutasteride; Other: Placebo Sponsors: University of Colorado, Denver; GlaxoSmithKline Terminated Mon, 28 Sep 2009 12:00:00 EDT Dutasteride for the Reduction of Alcohol Use in Male DrinkersConditions: Alcoholism; Alcohol Abuse; Alcohol DependenceInterventions: Drug: Dutasteride; Drug: Placebo Sponsors: UConn Health; National Institute on Alcohol Abuse and Alcoholism (NIAAA) Completed Fri, 17 Dec 2010 12:00:00 EST 
Dutasteride After Failure of Finasteride In the Management of Symptomatic Prostatic Enlargement/Hypertrophy (BPE/H)Condition: Benign Prostatic HypertrophyIntervention: Drug: Dutasteride Sponsor: North Florida/South Georgia Veterans Health System Completed Fri, 29 Sep 2006 12:00:00 EDT Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)Conditions: Kennedy's Disease; Spinal and Bulbar Muscular AtrophyInterventions: Drug: Dutasteride; Drug: Placebo Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) Completed Thu, 16 Mar 2006 12:00:00 EST AVODART(Dutasteride) Post-marketing Surveillance(PMS)Conditions: Benign Prostatic Hyperplasia; Prostatic HyperplasiaIntervention: Drug: Dutasteride Sponsor: GlaxoSmithKline Completed Fri, 18 Feb 2011 12:00:00 EST Bioequivalence - Duodart Against Avodart & OmnicCondition: Prostatic HyperplasiaInterventions: Drug: dutasteride/tamsulosin; Drug: dutasteride; Drug: tamsulosin Sponsor: GlaxoSmithKline Completed Mon, 06 Aug 2012 12:00:00 EDT Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate CancerCondition: Prostate CancerInterventions: Drug: Dutasteride; Drug: Placebo Sponsors: NorthShore University HealthSystem; University of Chicago; Northwestern University Completed Tue, 29 Apr 2008 12:00:00 EDT Dutasteride Treatment for the Reduction of Heavy Drinking in MenConditions: Alcoholism; Alcohol Abuse; Alcohol DependenceInterventions: Drug: Dutasteride; Drug: sugar pill Sponsors: UConn Health; National Institute on Alcohol Abuse and Alcoholism (NIAAA) Completed Tue, 01 Jan 2013 12:00:00 EST Bioequivalence Study of Dutasteride Capsules in Healthy Japanese Male SubjectsCondition: Prostatic HyperplasiaInterventions: Drug: Dutasteride-Test product; Drug: Dutasteride-Reference product Sponsor: GlaxoSmithKline Completed Mon, 19 Oct 2015 12:00:00 EDT Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate CancerCondition: Prostate CancerIntervention: Drug: Ketoconazole, Hydrocortisone and Dutasteride Sponsors: Beth Israel Deaconess Medical Center; Massachusetts General Hospital; Dana-Farber Cancer Institute; Sunnybrook Health Sciences Centre; Oregon Health and Science University; M.D. Anderson Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Completed Wed, 07 May 2008 12:00:00 EDT A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic AlopeciaCondition: AlopeciaIntervention: Drug: Dutasteride 0.5mg oral tablets Sponsor: GlaxoSmithKline Completed Wed, 28 Feb 2007 12:00:00 EST A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic AlopeciaCondition: AlopeciaIntervention: Drug: Dutasteride 0.5 mg Sponsor: GlaxoSmithKline Completed Mon, 15 Apr 2013 12:00:00 EDT
Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In MenCondition: Neoplasms, ProstateInterventions: Drug: Dutasteride; Drug: Matching placebo Sponsor: GlaxoSmithKline Completed Tue, 15 Aug 2006 12:00:00 EDT This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood SamplesCondition: Prostatic HyperplasiaIntervention: Drug: Dutasteride and Tamsulosin Sponsor: GlaxoSmithKline Completed Tue, 08 Oct 2013 12:00:00 EDT Role of Dutasteride in Treatment of Chronic ProstatitisConditions: Dutasteride; Category IIIB Chronic ProstatitisInterventions: Drug: Dutasteride 0.5 mg; Drug: Placebo Sponsor: Ain Shams University Completed Tue, 16 Feb 2021 12:00:00 EST Sexual Function in Men Receiving Dutasteride for Androgenetic AlopeciaCondition: AlopeciaInterventions: Drug: Dutasteride; Drug: Placebo Sponsors: Stiefel, a GSK Company; GlaxoSmithKline Completed Wed, 18 Dec 2013 12:00:00 EST Safety and Efficacy of 0.5mg Dutasteride and 0.4mg Tamsulosin Combination Once Daily for Six Months for Benign Prostatic HyperplasiaCondition: Prostatic HyperplasiaIntervention: Drug: Dutasteride/Tamsulosin Sponsor: GlaxoSmithKline Terminated Tue, 28 Aug 2012 12:00:00 EDT Extension Study of GI198745 to Treat Benign Prostatic HyperplasiaConditions: Benign Prostatic Hyperplasia; Prostatic HyperplasiaInterventions: Drug: GI198745 0.05mg; Drug: GI198745 0.5mg; Drug: GI198745 2.5mg Sponsor: GlaxoSmithKline Completed Mon, 31 Aug 2009 12:00:00 EDT Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination TreatmentCondition: Prostatic HyperplasiaInterventions: Drug: dutasteride 0.5mg once daily for 4 years; Drug: tamsulosin 0.4mg once daily for 4 years Sponsor: GlaxoSmithKline Completed Thu, 26 Aug 2004 12:00:00 EDT Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate CancerCondition: Prostate CancerIntervention: Drug: Dutasteride Sponsors: Canadian Urology Research Consortium; GlaxoSmithKline Completed Tue, 06 Nov 2007 12:00:00 EST Enzalutamide & Dutasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.Condition: Prostate CancerIntervention: Drug: Enzalutamide and Dutasteride Sponsor: University of Rochester Active, not recruiting Mon, 11 Aug 2014 12:00:00 EDT STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway SignalingCondition: Adenocarcinoma of the ProstateInterventions: Drug: STA9090; Drug: STA9090 with Dutasteride Sponsor: Toni Choueiri, MD Withdrawn Tue, 07 Jun 2011 12:00:00 EDT
Study to Compare the Bioavailability of Dutasteride Novel Formulation Form to the Soft Gel Capsule Form in Healthy Male SubjectsCondition: Prostatic HyperplasiaIntervention: Drug: dutasteride Sponsor: GlaxoSmithKline Completed Mon, 16 Apr 2012 12:00:00 EDT Effect of Dutasteride on HIF-1alpha and VEGF in the ProstateCondition: Benign Prostatic HyperplasiaIntervention: Drug: dutasteride Sponsors: Seoul National University Hospital; The Korean Urological Association; GlaxoSmithKline Completed Tue, 14 Apr 2009 12:00:00 EDT Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for BrachytherapyConditions: Prostate Cancer; Erectile Dysfunction; Lower Urinary Tract SymptomsInterventions: Drug: administration of a LHRH agonist and Bicalutamide; Drug: administration of Bicalutamide, Dutasteride and Tamoxifen Sponsors: CHU de Quebec-Universite Laval; GlaxoSmithKline Unknown status Fri, 20 Mar 2009 12:00:00 EDT Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate CancerCondition: Prostate CancerInterventions: Drug: Abiraterone acetate; Drug: Dutasteride; Drug: Prednisone Sponsor: Mary-Ellen Taplin, MD Completed Wed, 13 Jul 2011 12:00:00 EDT Safety and Pharmacokinetic Characteristics of DKF-313Conditions: Benign Prostate Hyperplasia; HealthyInterventions: Drug: DKF-313; Drug: AVODART; Drug: CIALIS Sponsor: Dongkook Pharmaceutical Co., Ltd. Completed Mon, 02 Feb 2015 12:00:00 EST Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)Conditions: Benign Prostatic Hyperplasia; Prostatic HyperplasiaInterventions: Drug: Dutasteride 0.5mg capsule; Drug: Dutasteride matched placebo Sponsor: GlaxoSmithKline Completed Tue, 11 Sep 2007 12:00:00 EDT Dutasteride (GI198745) In Benign Prostatic Hyperplasia SubjectsCondition: Prostatic HyperplasiaInterventions: Drug: Dutasteride; Drug: Placebo Sponsor: GlaxoSmithKline Completed Tue, 29 Aug 2006 12:00:00 EDT A Clinical Trial Comparing Laser TURP With and Without Dutasteride.Condition: Benign Prostatic HyperplasiaInterventions: Drug: Dutasteride (Avodart); Drug: Placebo Sponsors: Northwestern University; GlaxoSmithKline Terminated Tue, 06 Feb 2007 12:00:00 EST To Evaluate the Pharmacokinetics and Safety of AD-208Condition: Androgenetic AlopeciaInterventions: Drug: AD-208; Drug: Avodart Soft Capsule 0.5mg Sponsor: Addpharma Inc. Completed Thu, 02 Jan 2020 12:00:00 EST Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and TadalafilCondition: Benign Prostatic HyperplasiaInterventions: Drug: Dutasteride 0.5 mg; Drug: Tadalafil 5 mg; Drug: YY-201 Sponsor: Yuyu Pharma, Inc. Completed Mon, 07 Aug 2017 12:00:00 EDT
Effects of Testosterone Plus Dutasteride or Placebo on Muscle Strength, Body Composition and Metabolism in TransmenConditions: Transgenderism; HypogonadismInterventions: Drug: dutasteride 5 mg/day; Drug: Testosterone Undecanoate Sponsor: Unita Complessa di Ostetricia e Ginecologia Completed Fri, 11 Sep 2020 12:00:00 EDT Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its ProgressionConditions: Prostatic Neoplasms; Low Grade Prostate CancerInterventions: Other: Dietary intervention first; Drug: Drug (Dutasteride) intervention first Sponsors: CHU de Quebec-Universite Laval; Prostate Cancer Canada Active, not recruiting Tue, 31 Jul 2012 12:00:00 EDT Efficacy Study for Use of Dutasteride (Avodart) With Testosterone ReplacementCondition: HypogonadismInterventions: Drug: dutasteride; Drug: placebo Sponsors: The Miriam Hospital; GlaxoSmithKline Completed Tue, 16 Sep 2008 12:00:00 EDT Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male VolunteersCondition: AlopeciaInterventions: Drug: GI198745 0.1 mg; Drug: GI198745 0.5 mg Sponsor: GlaxoSmithKline Completed Tue, 27 Aug 2013 12:00:00 EDT TRADE-Testosterone Replacement and Dutasteride EffectivenessConditions: Hypogonadism; Benign Prostatic HyperplasiaInterventions: Drug: Dutasteride; Drug: Testosterone gel; Drug: Placebo dutasteride Sponsors: University of Washington; GlaxoSmithKline; Seattle Institute for Biomedical and Clinical Research; VA Office of Research and Development; Solvay Pharmaceuticals Completed Mon, 19 Sep 2005 12:00:00 EDT A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry.Condition: Prostatic HyperplasiaIntervention: Drug: Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg) Sponsor: GlaxoSmithKline Completed Mon, 06 Dec 2010 12:00:00 EST Prevention of Prostate Cancer With Dutasteride in Case of High Grade PIN NeoplasiaCondition: Prostate CancerInterventions: Drug: dutasteride; Procedure: prostate biopsy Sponsor: Kaunas University of Medicine Completed Tue, 28 Oct 2008 12:00:00 EDT Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male SubjectsCondition: Prostatic HyperplasiaInterventions: Drug: FDC capsule of dutasteride and tamsulosin; Drug: Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet Sponsor: GlaxoSmithKline Completed Mon, 27 Jul 2015 12:00:00 EDT Bioavailability of Two Combination Products of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) in Asian Males.Condition: Prostatic HyperplasiaInterventions: Drug: Dutasteride (0.5mg); Drug: FDC product of dutasteride (0.5mg) and tamsulosin HCl (0.2mg); Drug: Harnal D Tablets and Harnal Capsules (both comprising 0.2 mg tamsulosin HCl) Sponsor: GlaxoSmithKline Completed Wed, 16 Nov 2011 12:00:00 EST Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin Hydrochloride (HCL) Combination Capsule in Fasted StateCondition: Urologic DiseasesInterventions: Drug: Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg; Drug: Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule Sponsor: GlaxoSmithKline Completed Mon, 03 Feb 2014 12:00:00 EST
A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to AvodartCondition: Benign Prostatic HyperplasiaIntervention: Drug: Dutasteride Sponsor: Urologic Consultants of Southeastern PA Unknown status Thu, 05 Jun 2008 12:00:00 EDT Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral TestosteroneConditions: Contraception; HypogonadismInterventions: Drug: Oral Testosterone; Drug: Leuprolide (Lupron); Drug: Dutasteride Sponsors: University of Washington; GlaxoSmithKline; National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Completed Mon, 12 Sep 2005 12:00:00 EDT Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in Fed StateCondition: Urologic DiseasesInterventions: Drug: Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg; Drug: Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule Sponsor: GlaxoSmithKline Completed Mon, 10 Feb 2014 12:00:00 EST Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)Condition: Benign Prostatic Hyperplasia (BPH)Interventions: Drug: Tolterodine ER 4mg; Drug: Placebo; Drug: Pre-randomization Dutasteride Sponsors: Siami, Paul F., M.D.; GlaxoSmithKline; Pfizer Completed Tue, 14 Jul 2009 12:00:00 EDT Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate CancerConditions: Prostate Cancer; Castration-resistant, MetastaticIntervention: Other: testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride Sponsors: Memorial Sloan Kettering Cancer Center; GlaxoSmithKline; University of Washington Completed Mon, 02 Mar 2009 12:00:00 EST Finasteride, Dutasteride and Insulin ActionCondition: Healthy VolunteersInterventions: Drug: Finasteride; Drug: Dutasteride Sponsor: University of Birmingham Unknown status Wed, 14 Aug 2013 12:00:00 EDT Pharmacogenetics of Alcohol: Treatment ImplicationsConditions: Alcohol Related Disorders; Alcoholism; Alcohol AbuseInterventions: Drug: dutasteride + ethanol; Drug: placebo medication + ethanol; Drug: dutasteride + placebo alcohol; Drug: placebo medication + placebo alcohol Sponsors: UConn Health; National Institutes of Health (NIH); National Institute on Alcohol Abuse and Alcoholism (NIAAA) Completed Thu, 14 Aug 2008 12:00:00 EDT A Study to Investigate the Pharmacokinetic Drug Interactions Between Dutasteride and Tadalafil in Healthy Male SubjectsCondition: Benign Prostate HyperplasiaInterventions: Drug: Tadalafil; Drug: Dutasteride Sponsor: Yuyu Pharma, Inc. Completed Wed, 20 Jul 2016 12:00:00 EDT Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation TherapyCondition: Prostate CancerIntervention: Drug: dutasteride Sponsor: Roswell Park Cancer Institute Completed Thu, 23 Nov 2006 12:00:00 EST Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate CancerCondition: Prostate CancerInterventions: Drug: dutasteride; Other: placebo Sponsors: Sidney Kimmel Cancer Center at Thomas Jefferson University; National Cancer Institute (NCI) Completed Fri, 10 Nov 2006 12:00:00 EST
Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) LevelsCondition: Prostatic HyperplasiaIntervention: Drug: Dutasteride Sponsor: GlaxoSmithKline Completed Tue, 17 Jun 2003 12:00:00 EDT Dutasteride to Treat Women With Menstrually Related Mood DisordersConditions: Premenstrual Syndrome; PMS; Healthy; DepressionInterventions: Drug: Dutasteride; Drug: Placebo oral capsule Sponsor: National Institute of Mental Health (NIMH) Completed Wed, 28 Apr 2004 12:00:00 EDT 28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal MenConditions: Hypogonadism; Hypogonadism, MaleInterventions: Drug: Nanomilled testosterone; Drug: Nanomilled dutasteride; Drug: commercially available dutasteride Sponsor: GlaxoSmithKline Completed Fri, 10 Nov 2006 12:00:00 EST Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without DutasterideConditions: Hypogonadism; Hypogonadism, MaleInterventions: Drug: Nanomilled testosterone; Drug: commercially available dutasteride; Drug: Nanomilled dutasteride Sponsor: GlaxoSmithKline Completed Thu, 16 Nov 2006 12:00:00 EST EAT-DUTA AndroCoV TrialCondition: Covid19Interventions: Drug: Dutasteride 0.5 mg; Drug: Azithromycin; Drug: Nitazoxanide; Drug: Placebo Sponsor: Corpometria Institute Completed Thu, 28 Jan 2021 12:00:00 EST Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic HyperplasiaCondition: Benign Prostatic HyperplasiaIntervention: Drug: Tamsulosin Sponsors: Siami, Paul F., M.D.; GlaxoSmithKline Completed Thu, 19 Jun 2008 12:00:00 EDT Drug Use Investigation for AVOLVE(BPH)Condition: Prostatic HyperplasiaIntervention: Drug: Dutasteride Sponsor: GlaxoSmithKline Completed Mon, 20 Jun 2011 12:00:00 EDT Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic HyperplasiaCondition: Prostatic HyperplasiaInterventions: Drug: Dutasteride 0.5mg capsules; Drug: Dutasteride placebo capsules; Drug: Tamsulosin 0.2mg tablets; Drug: Disintegrating placebo tamsulosin tablet Sponsor: GlaxoSmithKline Completed Mon, 10 Feb 2014 12:00:00 EST Efficacy and Safety of DKF-313 in Patients With Benign Prostatic HyperplasiaCondition: Benign Prostatic HyperplasiaInterventions: Drug: DKF-313; Drug: Dutasteride; Drug: Tadalafil; Drug: DKF-313 placebo; Drug: Dutasteride placebo; Drug: Tadalafil placebo Sponsor: Dongkook Pharmaceutical Co., Ltd. Not yet recruiting Thu, 01 Jul 2021 12:00:00 EDT Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate EnlargementCondition: Prostatic HyperplasiaInterventions: Drug: Dutasteride plus tamsulosin; Drug: tamsulosin Sponsor: GlaxoSmithKline Completed Fri, 11 Feb 2011 12:00:00 EST
A Study Assessing a Range of Formulations of the Fixed Dose Combination Product Containing Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) to Find a Formulation Which is Bioequivalent to Harnal-D Tablets (Tamsulosin Hydrochloride, 0.2mg) in Healthy Male Subjects From North East AsiaCondition: Prostatic HyperplasiaInterventions: Drug: Dutasteride (0.5mg, fasted state); Drug: Dutasteride (0.5mg, fed state); Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state); Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fed state); Drug: Harnal-D Tablets with water (fasted state); Drug: Harnal-D Tablets with water (fed state); Drug: Harnal-D tablets without water (fasted state) Sponsor: GlaxoSmithKline Completed Mon, 19 Dec 2011 12:00:00 EST Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate CancerCondition: Prostate CancerIntervention: Drug: tamsulosin and/or dutasteride Sponsors: Case Comprehensive Cancer Center; GlaxoSmithKline Completed Wed, 26 Oct 2005 12:00:00 EDT Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate CancerCondition: Prostate CancerInterventions: Drug: ketoconazole; Drug: hydrocortisone; Drug: dutasteride; Drug: lapatinib Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Massachusetts General Hospital; Prostate Cancer Foundation Clinical Research Consortium; GlaxoSmithKline Terminated Thu, 06 Aug 2009 12:00:00 EDT Safety and Pharmacokinetic Interaction Study of Tadalafil and DutasterideCondition: Benign Prostate HyperplasiaInterventions: Drug: Tadalafil; Drug: Dutasteride Sponsor: Dongkook Pharmaceutical Co., Ltd. Completed Mon, 16 Sep 2013 12:00:00 EDT Dutasteride Versus Placebo and Finasteride in Men With Androgenetic AlopeciaCondition: Androgenetic AlopeciaInterventions: Drug: 1mg Finasteride active; Drug: 0.02mg dutasteride; Drug: 0.1mg dutasteride; Drug: 0.5mg dutasteride; Drug: Finasteride placebo; Drug: Dutasteride placebo Sponsor: GlaxoSmithKline Completed Mon, 01 Nov 2010 12:00:00 EDT Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate CancerConditions: Benign Prostatic Hyperplasia; Prostate CancerIntervention: Drug: Dutasteride Sponsor: GlaxoSmithKline Completed Wed, 13 Sep 2006 12:00:00 EDT "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased RiskCondition: Neoplasms, ProstateInterventions: Drug: Dutasteride; Drug: Placebo Sponsor: GlaxoSmithKline Completed Thu, 13 Mar 2003 12:00:00 EST Validation of Digital Morphometry for Cancer Risk in Benign Prostate BiopsiesCondition: Prostate CancerInterventions: Drug: Dutasteride; Drug: Placebo Sponsors: University of Illinois at Chicago; National Cancer Institute (NCI) Completed Wed, 09 May 2012 12:00:00 EDT A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted StateCondition: Prostatic HyperplasiaInterventions: Drug: Treatment sequence A; Drug: Treatment sequence B; Drug: Treatment sequence C; Drug: Treatment sequence D Sponsor: GlaxoSmithKline Completed Mon, 01 Oct 2007 12:00:00 EDT Oral Androgens in Man-4: (Short Title: Oral T-4)Condition: ContraceptionInterventions: Drug: Testosterone Enanthate; Drug: Dutasteride; Other: placebo sesame oil Sponsors: University of Washington; GlaxoSmithKline Completed Tue, 14 Nov 2006 12:00:00 EST
Treatment of Refractory Urinary Retention Secondary to Benign Prostatic Hyperplasia (BPH) With Dual Five Alpha Reductase Inhibition Combined With an Alpha BlockerConditions: Urinary Retention; Benign Prostatic HyperplasiaIntervention: Drug: Dutasteride Sponsor: Franklin D. Gaylis, MD Inc. Completed Tue, 20 May 2008 12:00:00 EDT A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomyConditions: Prostate Cancer; Localized Prostate CancerInterventions: Drug: Enzalutamide; Drug: Abiraterone acetate; Drug: Prednisone; Drug: Dutasteride; Drug: Degarelix Sponsors: Kenneth Pienta, MD; Prostate Cancer Foundation Norway Withdrawn Tue, 10 Jun 2014 12:00:00 EDT A Study To Compare 3 Different Formulations Of Tamsulosin At Steady State.Condition: Prostatic HyperplasiaIntervention: Drug: GI198745 Sponsor: GlaxoSmithKline Completed Thu, 07 Feb 2008 12:00:00 EST Dutasteride in Treating Patients With Prostate CancerCondition: Prostate CancerInterventions: Drug: dutasteride; Drug: gadolinium-chelate; Other: active surveillance; Procedure: diffusion-weighted magnetic resonance imaging; Procedure: functional magnetic resonance imaging; Procedure: prostate biopsy; Procedure: ultrasound imaging Sponsor: University College London Hospitals Unknown status Thu, 02 Sep 2010 12:00:00 EDT Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation TherapyCondition: Neoplasms, ProstateInterventions: Drug: dutasteride; Drug: placebo; Drug: bicalutamide Sponsor: GlaxoSmithKline Completed Tue, 08 May 2007 12:00:00 EDT Economic Analyses of the REDUCE TrialConditions: Neoplasms, Prostate; Benign Prostatic Hyperplasia; CancerInterventions: Drug: Dutasteride; Drug: Placebo Sponsor: GlaxoSmithKline Completed Mon, 18 Apr 2011 12:00:00 EDT Pharmacovigilance Study To Evaluate Safety Of AVODART In Subjects With Benign Prostate HyperplasiaCondition: Benign Prostatic HyperplasiaIntervention: Sponsor: GlaxoSmithKline Completed Tue, 15 Jan 2008 12:00:00 EST Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate CancerCondition: Prostate CancerInterventions: Drug: Bicalutamide; Drug: Dutasteride; Drug: Finasteride; Radiation: Radiation Sponsor: University of Chicago Active, not recruiting Wed, 27 Apr 2011 12:00:00 EDT Long-term Effects of Dutasteride on Architectural and Nuclear Morphometric Features of Benign Prostate TissueCondition: Benign Prostate TissueIntervention: Sponsors: University of Illinois at Chicago; GlaxoSmithKline Completed Thu, 17 Nov 2011 12:00:00 EST Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASISCondition: Prostatic HyperplasiaInterventions: Procedure: IPSS Questionnaire; Procedure: EQ-5D Questionnaire Sponsor: GlaxoSmithKline Completed Fri, 21 Apr 2006 12:00:00 EDT
ARI103094-Follow-Up Study for REDUCE Study SubjectsCondition: Neoplasms, ProstateIntervention: Drug: dutasteride Sponsor: GlaxoSmithKline Completed Mon, 20 Apr 2009 12:00:00 EDT ITT-5 Mechanisms of Spermatogenesis in ManCondition: Gonadotropin DeficiencyInterventions: Drug: Testosterone 1% Gel; Drug: Acyline; Drug: Dutasteride; Drug: Ketoconazole; Drug: HCG; Drug: placebo dutasteride; Drug: placebo ketoconazole Sponsor: University of Washington Withdrawn Wed, 28 May 2014 12:00:00 EDT Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan DatabaseCondition: Prostatic HyperplasiaIntervention: Drug: 5ARI Sponsor: GlaxoSmithKline Completed Mon, 20 Jun 2011 12:00:00 EDT Metabolic Effects of Steroids in Obese MenConditions: Obesity; Insulin ResistanceInterventions: Drug: Anastrazole; Drug: Testosterone; Drug: Dutasteride; Drug: GnRH antagonist Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of California, San Diego Unknown status Thu, 24 Sep 2009 12:00:00 EDT Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate CancerCondition: Prostate CancerInterventions: Drug: Enzalutamide; Drug: Leuprolide; Drug: Dutasteride Sponsors: Pfizer; Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc. Completed Wed, 07 Mar 2012 12:00:00 EST Maximal Suppression of the Androgen Axis in Clinically Localized Prostate CancerConditions: Cancer; Prostate NeoplasmsInterventions: Drug: goserelin with dutasteride; Drug: goserelin with bicalutamide and dutasteride; Drug: goserelin with bicalutamide and dutasteride and ketoconazole Sponsors: University of Washington; GlaxoSmithKline; AstraZeneca Completed Wed, 01 Mar 2006 12:00:00 EST Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted StatesCondition: Prostatic HyperplasiaInterventions: Drug: Treatment sequence A; Drug: Treatment sequence B; Drug: Treatment sequence C Sponsor: GlaxoSmithKline Completed Wed, 09 Jul 2014 12:00:00 EDT Combination Statin, Acetylsalicylic Acid and Dutasteride Use in Prostate CancerCondition: Prostate CancerIntervention: Sponsor: University Health Network, Toronto Completed Mon, 05 Sep 2011 12:00:00 EDT Prospective Sexual Function Study for BPH SubjectsCondition: Prostatic HyperplasiaInterventions: Drug: Dutasteride plus tamsulosin; Drug: Placebo Sponsor: GlaxoSmithKline Completed Mon, 28 Jan 2013 12:00:00 EST Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan DatabaseCondition: Prostatic HyperplasiaIntervention: Drug: 5-alpha Reductase Inhibitor (5ARI) Sponsor: GlaxoSmithKline Completed Mon, 27 Jun 2011 12:00:00 EDT
Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor UseCondition: Prostatic HyperplasiaIntervention: Drug: 5ARI + AB Sponsor: GlaxoSmithKline Completed Mon, 11 Apr 2011 12:00:00 EDT Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database AssessmentCondition: Prostatic HyperplasiaInterventions: Drug: 5ARI; Drug: 5ARI + AB Sponsor: GlaxoSmithKline Completed Fri, 01 Jul 2011 12:00:00 EDT Α Prospective Observational Study for the Evaluation of Disease Control and Quality of Life in Patients With Benign PROStatic hyPERplasia Under Fixed Dose combΙnaTion Treatment With Dutasteride and Tamsulosin as Well as Their qualitY of LifeCondition: Benign Prostatic HyperplasiaIntervention: Other: Patients with Benign Prostate Hyperplasia Sponsor: Elpen Pharmaceutical Co. Inc. Not yet recruiting Mon, 05 Apr 2021 12:00:00 EDT JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)Conditions: Benign Prostatic Hyperplasia; Chronic ProstatitisInterventions: Drug: Jalyn; Drug: Placebo Sponsors: Dr. J. Curtis Nickel; The Cleveland Clinic; University of California, Los Angeles Terminated Fri, 12 Apr 2013 12:00:00 EDT Testosterone and Its Metabolites in GIDCondition: TranssexualismInterventions: Drug: testosterone undecanoate alone; Drug: testosterone undecanoate plus letrozole; Drug: testosterone undecanoate plus dutasteride Sponsors: Unita Complessa di Ostetricia e Ginecologia; Schering-Plough Completed Mon, 05 Sep 2005 12:00:00 EDT PROS-1-Male Hormonal Contraceptive Regimens on Prostate TissueCondition: HealthyInterventions: Drug: Testosterone gel; Drug: Dutasteride; Drug: Depo-Medroxyprogesterone (DMPA); Other: Placebo Testosterone gel; Other: Placebo dutasteride; Other: Placebo DMPA Sponsors: University of Washington; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Completed Fri, 22 Jun 2007 12:00:00 EDT Study of PCUR-101 in Combination With ADT in Patients With mCRPCCondition: Prostate CancerInterventions: Drug: PCUR-101; Drug: Dutasteride 0.5 mg; Drug: Abiraterone and Prednisone Sponsor: Pellficure Pharmaceuticals, Inc Recruiting Mon, 21 Dec 2020 12:00:00 EST For Cause Prostate Biopsy in REDUCE Population TrialCondition: Prostate CancerIntervention: Sponsors: The Cleveland Clinic; GlaxoSmithKline Completed Wed, 08 Feb 2012 12:00:00 EST Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic HyperplasiaCondition: Prostatic HyperplasiaInterventions: Drug: Adherent with 5-alpha-reductase inhibitor (5ARI) therapy; Drug: Non-adherent to 5ARI therapy Sponsor: GlaxoSmithKline Completed Wed, 13 Apr 2011 12:00:00 EDT The Utility of PSADv (PSA Density Velocity) While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and StageCondition: Prostate CancerIntervention: Sponsor: University Urological Associates Inc. Unknown status Fri, 02 Dec 2011 12:00:00 EST
An Observational Study of Dutasteride and Alpha-blocker Combination Therapy in Men With Symptomatic Benign Prostatic Hyperplasia and PSA Level Over 4 ng/mLCondition: Benign Prostatic HyperplasiaIntervention: Sponsor: Taipei Medical University WanFang Hospital Unknown status Wed, 11 May 2011 12:00:00 EDT The Role of 5-alpha Reductase in Mediating Testosterone ActionsCondition: HealthyInterventions: Drug: Testosterone Enanthate; Drug: Dutasteride Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Completed Fri, 29 Jun 2007 12:00:00 EDT ITT4 Intratesticular Hormonal Milieu in Man (ITT4)Condition: Healthy MalesInterventions: Drug: Acyline; Drug: Testosterone gel; Drug: ketoconazole 400; Drug: Ketoconazole 800; Drug: Dutasteride; Drug: Anastrozole; Drug: Placebo ketoconazole Sponsors: University of Washington; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Completed Wed, 06 Oct 2010 12:00:00 EDT Testosterone-Driven Growth-Hormone (GH) Secretion in Aging MenCondition: AgingInterventions: Drug: Placebo; Drug: Testosterone; Drug: Anastrazole; Drug: Dutasteride Sponsors: Mayo Clinic; GlaxoSmithKline Completed Mon, 03 Apr 2006 12:00:00 EDT Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination TherapyCondition: Benign Prostatic HyperplasiaInterventions: Drug: Early combination therapy; Drug: Delayed combination therapy Sponsor: GlaxoSmithKline Completed Mon, 19 Sep 2011 12:00:00 EDT Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic HyperplasiaCondition: Benign Prostatic HyperplasiaInterventions: Device: Embosphere® (Prostatic Arteries Embolization); Drug: Drug therapy Sponsors: Assistance Publique - Hôpitaux de Paris; Ministry of Health, France Active, not recruiting Wed, 17 Aug 2016 12:00:00 EDT Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to AdherenceCondition: Prostatic HyperplasiaIntervention: Drug: 5ARI or AB or Combination Therapy (5ARI + AB) Sponsor: GlaxoSmithKline Completed Mon, 11 Jul 2011 12:00:00 EDT 5 Alpha Reductase Inhibitors And The Risk Of Suicide And DepressionConditions: BPH; Depression; SuicideIntervention: Drug: 5ARI Sponsor: Lawson Health Research Institute Completed Wed, 24 Aug 2016 12:00:00 EDT Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic HyperplasiaCondition: Prostatic HyperplasiaIntervention: Drug: 5ARI + AB Sponsor: GlaxoSmithKline Completed Mon, 11 Apr 2011 12:00:00 EDT One-year Prospective Observational Study of BMI Change Effect of 5-alpha Reductase Inhibitor in Korean BPH PatientsCondition: Benign Prostatic HyperplasiaIntervention: Sponsors: Seoul National University Hospital; GlaxoSmithKline; Seoul National University Bundang Hospital Completed Fri, 11 May 2007 12:00:00 EDT
Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: MarketscanCondition: Prostatic HyperplasiaInterventions: Drug: 5ARI; Drug: AB Sponsor: GlaxoSmithKline Completed Mon, 28 Mar 2011 12:00:00 EDT Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPHConditions: Benign Prostatic Hyperplasia; Pharmacotherapy; Prostatic Artery Embolization; Minimally Invasive TreatmentInterventions: Procedure: Prostatic Artery Embolization (PAE); Drug: Pharmacotherapy Sponsor: Dominik Abt Not yet recruiting Wed, 29 Jan 2020 12:00:00 EST |